SUMMIT Trial Proves Tirzepatide's Benefit in HFpEF with Obesity

The benefit was driven by a reduction in the risk of worsening HF events resulting in hospitalization, intravenous drug therapy in an urgent ...

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the ...

American Heart Association Scientific Sessions 2024, Abstract 4171195 - In an international trial of 713 adults in nine countries including ...

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately ...

In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity.

The SUMMIT trial showed that among obese patients with HFpEF, once weekly subcutaneous tirzepatide was superior to placebo in improving the ...

For Obesity and HFpEF, Tirzepatide Cuts Risk of CV Death or Worsening HF by 38% ... “The SUMMIT trial is the first trial in patients with HFpEF ...

For the SUMMIT trial, 731 patients with heart failure and an ejection fraction of at least 50%, who also had obesity defined as a body mass ...

The Phase 3 study, known as SUMMIT, revealed that tirzepatide reduces the risk of death or serious complications from heart failure by 38 ...

Trial Name: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The ...

Tirzepatide treatment led to meaningful improvements on a widely used assessment of heart failure symptoms, the study's other main goal. Results ...

Tirzepatide slashes heart failure risk by 38% in phase 3 study · SUMMIT Results: Tirzepatide for HFpEF and Obesity ...

In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity.".

The SUMMIT trial involved 731 adults, including 54% women, who were followed for least 52 weeks (HR, 0.62; 95% CI, 0.41-0.95; P = .026).

In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity.".

Findings In this cohort study of 140 308 patients with type 2 diabetes, treatment with tirzepatide was associated with significantly lower ...

Tirzepatide reduced heart failure hospitalization or cardiovascular death risk by 38% in HFpEF patients with obesity. · The SUMMIT trial showed a ...

Overall, tirzepatide's dual agonism of GLP1 and GIP receptors appears to provide encouraging cardiovascular benefits beyond glycemic control, ...

Future large-scale clinical trials, such as SURPASS-CVOT and SUMMIT, are expected to further verify the long-term benefits of tirzepatide in ...

Packer stressed that SUMMIT is the first GLP-1 receptor agonist trial powered to assess major HF outcomes in HFpEF with obesity. Previously, the ...